Equities

Skye Bioscience Inc

SKYE:NMQ

Skye Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.17
  • Today's Change-0.11 / -2.57%
  • Shares traded100.88k
  • 1 Year change+159.01%
  • Beta1.7549
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Skye Bioscience Inc's net income fell 93.23% from a loss of 19.48m to a larger loss of 37.64m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-43.73%
Return on equity-54.82%
Return on investment-54.60%
More ▼

Cash flow in USDView more

In 2023, Skye Bioscience Inc increased its cash reserves by 727.52%, or 9.09m. Cash Flow from Financing totalled 16.44m or -- of revenues. In addition the company used 13.95m for operations while cash from investing totalled 6.60m.
Cash flow per share-0.7155
Price/Cash flow per share--
Book value per share2.50
Tangible book value per share2.50
More ▼

Balance sheet in USDView more

Skye Bioscience Inc uses little or no debt in its capital structure.
Current ratio14.19
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 38.74%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
90.35
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.